US FDA successfully completes inspection at Indoco’s API Kilo Lab manufacturing facility and IAS division without any observations

Our Bureau, Mumbai

Thursday, May 16, 2024, 16:30 Hrs [IST]

Indoco Remedies Limited announced that the United States Food and Drug Administration (FDA) successfully completed inspection of its API Kilo Lab manufacturing facility at Rabale, Navi Mumbai and Indoco Analytical Solutions (IAS) division. The inspection concluded with zero Form 483 observations, reflecting the company's commitment to maintaining the highest standards of quality and compliance.

“We are extremely happy with the outcome of this inspection. This achievement reflects our relentless focus on quality and compliance in everything we do. We remain committed to ensuring the safety and efficacy of our products while maintaining the trust of our customers and stakeholders”, said Ms. Aditi Panandikar, managing director, Indoco Remedies Limited.

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company’s turnover is US$ 212 million with a human capital of over 6,000 employees, including over 400 skilled scientists and Field Staff who are the strength of the organization.